Cutaneous and histopathological features of drug reaction with eosinophila and systemic symptoms differ by HIV status in an HIV-endemic setting
Open Access
- 26 March 2026
- journal article
- Published by Elsevier in JAAD International
- Vol. 26, 70-72
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01AI152183)
- National Institute of Child Health and Human Development (D43 TW010559)
- Fogarty International Center
- National Research Foundation
- European Commission (TMA2017SF-1981)
- South African Medical Research Council
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institute of Allergy and Infectious Diseases
This publication has 5 references indexed in Scilit:
- Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic SymptomsJAMA Dermatology, 2024
- Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotypeJournal of the American Academy of Dermatology, 2021
- Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current PracticeThe Journal of Allergy and Clinical Immunology: In Practice, 2017
- Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR studyBritish Journal of Dermatology, 2013
- Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 casesBritish Journal of Dermatology, 2013